Gencor™ Announces Significant Results from its Study on the Effect of Levagen®+ in Reducing Joint Discomfort
Results showed significant decrease in VAS scores over 14 days of treatment
Gencor™, worldwide supplier of branded ingredients, has reported positive results on reducing joint discomfort with Levagen+® in a recently published study in the International Journal of Nutrition and Food Sciences. The study assessed the efficacy of dispersible Palmitoylethanolamide – PEA (Levagen+) for alleviating joint discomfort and improving quality of life in adults.
Levagen+ PEA is powered by LipiSperse®, Pharmako Biotechnologies’ cold water dispersion technology and has been shown to increase the absorption of PEA vs. standard PEA. The randomized, double-blind study compared the efficacy of a 350 mg dose of Levagen+ PEA to placebo on relieving joint discomfort in healthy adults aged between 25 and 70 years. Participants in the PEA group consumed 175 mg of Levagen+ twice daily (morning and night) with water over a two-week period.
“We are thrilled with the results of this study that further validates the potent effects of Levagen+ and suggests that PEA may be a safe and beneficial treatment for individuals with joint health related concerns,” said Chase Shryoc, Vice President of Sales & Business Development for Gencor. “With its anti-inflammatory and analgesic proprieties, along with its ability to influence the endocannabinoid system, Levagen+ PEA can play a critical role in supporting joint function.”
During this study, both groups demonstrated an early reduction in VAS (visual analog scale) pain scores compared to baseline values until approximately day 10. On day 10, the scores plateaued and increased in the placebo group while continuing to decrease in the PEA group, demonstrating the efficacy of PEA at reducing joint discomfort compared to placebo over the 14-day study period. The study also validated the bioavailability effects of dispersible PEA (Levagen+) vs. standard PEA by utilizing a lower dose (350 mg) compared to 600 mg dose of standard PEA that was used in previous trials to study PEA’s benefits for joint health.
Levagen+’s dispersion technology gives formulators the versatility to include Levagen+ into effervescent tablets, RTD shots, functional foods, functional beverages, and gummies.
For more information on Levagen+, visit: www GencorPacific.com